Novel migraine relief autoinjector approved by FDA

The U.S. Food and Drug Administration has approved the use of a dihydroergotamine mesylate autoinjector to treat patients with migraine in adults.

Dihydroergotamine is already an effective in-hospital treatment for headache relief, according to a news report from GlobeNewswire. The autoinjector was designed for the self-administration of one milligram of dihydroergotamine subcutaneously and may particularly benefit those who have adverse reactions to standard oral drugs.

Individuals who experience migraine should consult their clinicians to determine whether the autoinjector formulation may be appropriate for them. The treatment is expected to be available in the second half of 2025.

Read more: GlobeNewswire

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.